What Researchers Did
Researchers retrospectively evaluated the feasibility and efficacy of radiotherapy using intensity-modulated radiotherapy boosts after hyperbaric oxygen therapy with chemotherapy in 24 glioblastoma patients.
What They Found
All patients completed the planned radiotherapy dose, with only one patient (4%) terminating hyperbaric oxygen therapy due to Grade 2 aural pain. Toxicities were mild, with no Grade 3-5 non-hematological toxicity observed. The 2-year overall survival rate was 46.5%, and the 2-year progression-free survival rate was 35.4%, with a median overall survival time of 22.1 months.
What This Means for Canadian Patients
This combined therapy could offer a new, potentially feasible and promising treatment option for Canadian patients diagnosed with glioblastoma. Patients might experience improved survival rates with manageable side effects compared to existing treatments.
Canadian Relevance
This study has no direct Canadian connection as it was conducted in Japan.
Study Limitations
A key limitation of this study is its retrospective design and small sample size, which limits the generalizability of the findings.